how to mix thymosin alpha-1: Frequently asked questions

The peptide is likely partially denatured, but the extent is impossible to determine without lab analysis. Foam formation immediately after injection is the clearest sign of structural damage. If you see sustained foam (bubbles that persist for more than 10 seconds), discard the vial and start over with a new one. If no foam formed and the solution cleared within 90 seconds, the peptide may still be viable. But potency is uncertain. When working with research-grade peptides from Real Peptides, precise amino-acid sequencing and small-batch synthesis reduce baseline fragility, but reconstitution technique still determines final usability.

Discard the vial. Freezing reconstituted peptides causes ice crystal formation that physically disrupts peptide structure. The crystals act as microscopic blades that shear peptide bonds. This damage is irreversible and not visually detectable. The solution may appear normal after thawing, but bioactivity is lost. Standard refrigerator temperature is 2–8°C; if your unit runs colder (some older models fluctuate to 0°C), place the vial in the door shelf where temperature is most stable, or use a refrigerator thermometer to verify the internal temperature stays above 2°C.

Stop swirling and refrigerate the vial for 10–15 minutes, then attempt gentle swirling again. Refrigeration slows molecular motion, which paradoxically helps some aggregated peptides re-dissolve by reducing kinetic collisions that reinforce aggregation. If the solution remains cloudy or contains visible particles after this step, the peptide has irreversibly aggregated. Likely due to improper storage before you received it (temperature excursion during shipping or prolonged storage above −20°C). Do not use cloudy solutions; thymosin alpha-1's immune-modulating activity depends on correct tertiary structure, which aggregation destroys.

Sterile water lacks the benzyl alcohol preservative that prevents bacterial growth, so the reconstituted solution must be used within 24–48 hours and stored under strict sterile conditions. Every subsequent needle puncture introduces contamination risk without bacteriostatic protection. If you've already reconstituted with sterile water, draw the entire solution into multiple insulin syringes immediately (one syringe per planned dose), cap each syringe, and refrigerate. This eliminates repeated vial punctures. Use all doses within 48 hours. For multi-week protocols, reconstitute only what you'll use in two days and keep the remaining powder refrigerated until needed.

Recalculate your dose volume immediately. Do not attempt to remove excess water from the vial. If you added 1.2mL instead of 0.8mL to a 4.3mg vial, your actual concentration is now 3.58mg/mL instead of 5.38mg/mL. Update your calculator with the new water volume and it will output the corrected syringe units to draw. The peptide remains stable at lower concentrations; the only consequence is that you'll need to draw larger volumes per dose.

Use a larger injection volume instead of attempting to measure sub-0.5mL bacteriostatic water additions. If your mix Thymosin Alpha-1 calculator outputs 0.3mL for a 10mg/mL target concentration, the measurement precision on most syringes degrades below 30 units. Meaning your actual added volume could vary by ±15%. Instead, adjust your target concentration downward: aim for 5mg/mL (requiring 0.86mL for a 4.3mg vial), which allows you to draw 0.6mL per 3mg dose with far better accuracy.

Assume 85% of the labelled peptide mass as a conservative default and dose accordingly until you can verify actual content. For a vial labelled '5mg', enter 4.25mg into your mix Thymosin Alpha-1 calculator. This prevents overdosing while accounting for the typical 10–15% reduction from salt correction and lyophilisation loss. If possible, request a CoA retroactively from your supplier. Any reputable peptide source should provide batch-specific purity and net content data.